Shares of Liquidia (LQDA) are down $4.22, or 23%, to $13.80 in pre-market trading after Insmed (INSM) announced positive topline results from its randomized, double-blind, placebo-controlled Phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder, or TPIP, administered once daily in patients with pulmonary arterial hypertension.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia price target raised to $32 from $25 at Needham
- Liquidia Advances with YUTREPIA After Court Ruling
- Liquidia schedules first commercial shipment of YUTREPIA
- Liquidia Technologies: Strong Market Position and Growth Potential Amid Legal Clarity and Strategic Advancements
- Legal Victory and Promising Clinical Profile Boost Liquidia Technologies’ Market Prospects